Hemato Hemato has set itself the task of automating and fully objectifying the clinical analysis of blood data – known as cytometry – to enable personalized treatment for each person's immune system. Elaia Partners, Heal Capital, and High-Tech Gründerfonds (HTGF) are supporting the startup's mission with a €3.6 million seed financing round. With this funding, Hemato aims to scale its decision support software for blood cancer in European laboratories and provide an initial demonstration of the significant improvement in diagnostic quality.
Hemato supports cytometry workflow
Based on a constantly growing database of cytometry data from various sources, Hemato has developed algorithms that can predict disease biomarkers directly from the raw blood pressure meter data. Until now, the lack of standardized measurement protocols led to complex data variations that prevented automation. Hemato specializes in combining data from various sources to identify predictive disease biomarkers. The team has already used this technology in clinical routine for decision support in two laboratories – the Institute of Hematopathology in Hamburg and the Result Laboratory in Dordrecht. Now the Startupto increase the number of users and supported clinical pictures and to further improve the quality of the AI models.
Karsten Miermans, Co-founder and CEO of Hemato, explains:
"When we founded Hemato, we had no idea how much our AI capabilities would advance immunomedicine. As the highly complex immune system increasingly becomes a target for therapies, we believe there will be a rapidly growing demand for AI models trained on large databases to enable precision immune diagnostics. We are delighted to have the support of Elaia, Heal Capital, and the HTGF in addressing one of the greatest challenges in modern medicine."
Nik Raupp, Senior Investment Manager at HTGF, says:
"We are very impressed by the speed and quality of the Hemato team's AI development so far. We look forward to the next steps in improving leukemia diagnostics in this great consortium."
